<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#faf0be"},
{source: "3: Additional ", target: "3: uncertainties", fill: "#faf0be"},
{source: "3: uncertainties", target: "3: presently known", fill: "#faf0be"},
{source: "3: presently known", target: "3: the Company ", fill: "#faf0be"},
{source: "3: the Company ", target: "3: immaterial may also impair", fill: "#faf0be"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#faf0be"},
{source: "3: Additional ", target: "4: risks could harm", fill: "#e4d00a"},
{source: "4: risks could harm", target: "4: Companys ", fill: "#e4d00a"},
{source: "4: risks could harm", target: "10: substantially", fill: "#e25822"},
{source: "10: substantially", target: "10: major manufacturers", fill: "#e25822"},
{source: "10: major manufacturers", target: "10: contact lenses refused", fill: "#e25822"},
{source: "10: contact lenses refused", target: "10: sell lenses", fill: "#e25822"},
{source: "10: sell lenses", target: "10: direct marketers", fill: "#e25822"},
{source: "10: direct marketers", target: "10: of the Company ", fill: "#e25822"},
{source: "10: of the Company ", target: "10: distributors", fill: "#e25822"},
{source: "10: substantially", target: "24: The FCLCA ", fill: "#7851a9"},
{source: "24: The FCLCA ", target: "24: contact lenses only", fill: "#7851a9"},
{source: "24: contact lenses only", target: "24: based on", fill: "#7851a9"},
{source: "24: based on", target: "24: valid prescription", fill: "#7851a9"},
{source: "24: The FCLCA ", target: "26: previous legal risk", fill: "#cd5b45"},
{source: "26: previous legal risk", target: "26: uncertainty associated with numerous differing", fill: "#cd5b45"},
{source: "26: uncertainty associated with numerous differing", target: "26: often ambiguous", fill: "#cd5b45"},
{source: "26: often ambiguous", target: "26: regulations", fill: "#cd5b45"},
{source: "26: regulations", target: "26: previously governed", fill: "#cd5b45"},
{source: "26: previously governed", target: "26: Companys ", fill: "#cd5b45"},
{source: "26: Companys ", target: "26: requirements", fill: "#cd5b45"},
{source: "26: requirements", target: "26: canceling", fill: "#cd5b45"},
{source: "26: canceling", target: "26: customers orders due", fill: "#cd5b45"},
{source: "26: customers orders due", target: "26: prescriptions", fill: "#cd5b45"},
{source: "26: prescriptions", target: "26: otherwise invalid", fill: "#cd5b45"},
{source: "26: previous legal risk", target: "38: the Company ", fill: "#aa381e"},
{source: "38: the Company ", target: "38: contact lenses there", fill: "#aa381e"},
{source: "38: contact lenses there", target: "38: could secure", fill: "#aa381e"},
{source: "38: could secure", target: "38: adequate sources", fill: "#aa381e"},
{source: "38: adequate sources", target: "38: such supply could", fill: "#aa381e"},
{source: "38: such supply could", target: "38: terms no less", fill: "#aa381e"},
{source: "38: terms no less", target: "38: current supply which could", fill: "#aa381e"},
{source: "38: current supply which could", target: "38: adversely", fill: "#aa381e"},
{source: "38: adversely", target: "38: by increasing", fill: "#aa381e"},
{source: "38: by increasing", target: "38: adequate replacement supply cannot", fill: "#aa381e"},
{source: "38: adequate replacement supply cannot", target: "38: secured reducing", fill: "#aa381e"},
{source: "38: the Company ", target: "START_HERE", fill: "#aa381e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Internet Software and Services</td>
    </tr>
    <tr>
      <td>Internet Retail</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lluís_Companys">Lluís Companys</a></td>
      <td>Lluís Companys i Jover (Catalan pronunciation: [ʎuˈis kumˈpaɲs]; 21 June 1882 – 15 October 1940) was a Spanish politician from Catalonia who served as president of Catalonia from 1934 and during the Spanish Civil War.\nCompanys was a lawyer close to labour movement and one of the most prominent leaders of the Republican Left of Catalonia (ERC) political party, founded in 1931.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Passeig_de_Lluís_Companys,_Barcelona">Passeig de Lluís Companys, Barcelona</a></td>
      <td>Passeig de Lluís Companys (Catalan pronunciation: [pəˈsɛdʒ də ʎuˈis kumˈpaɲs]) is a promenade in the Ciutat Vella and Eixample districts of Barcelona, Catalonia, Spain, and can be seen as an extension of Passeig de Sant Joan. It was named after President Lluís Companys, who was executed in 1940.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estadi_Olímpic_Lluís_Companys">Estadi Olímpic Lluís Companys</a></td>
      <td>Estadi Olímpic Lluís Companys (Catalan pronunciation: [əsˈtaði uˈlimpiɡ ʎuˈis kumˈpaɲs], formerly known as the Estadi Olímpic de Montjuïc and Estadio de Montjuic) is a stadium in Barcelona, Catalonia, Spain. Originally built in 1927 for the 1929 International Exposition in the city (and Barcelona's bid for the 1936 Summer Olympics, which were awarded to Berlin), it was renovated in 1989 to be the main stadium for the 1992 Summer Olympics and 1992 Summer Paralympics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Víctor_Gay_Zaragoza">Víctor Gay Zaragoza</a></td>
      <td>Víctor Gay Zaragoza (born 19 June 1982 in Barcelona, Spain) is a writer, storyteller, trainer and consultant on storytelling. He is author of the essays "Filosofía Rebelde" (Rebel Philosophy), "50 libros que cambiarán tu vida" (50 books that will change your life) and the historical novel "El defensor" (The defender).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Scleral_lens">Scleral lens</a></td>
      <td>A scleral lens, also known as a scleral contact lens,  is a large contact lens that rests on the sclera and creates a tear-filled vault over the cornea. Scleral lenses are designed to treat a variety of eye conditions, many of which do not respond to other forms of treatment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_soft_contact_lens_materials">List of soft contact lens materials</a></td>
      <td>Soft contact lenses are one of several types of contact lenses for corrective vision eyewear as prescribed by optometrists and ophthalmologists.\n\n\n== Background ==\nIn the US market, soft contact lenses are approved by the US Food and Drug Administration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intraocular_lens">Intraocular lens</a></td>
      <td>Intraocular lens (IOL) is a lens implanted in the eye as part of a treatment for cataracts or myopia. If the natural lens is left in the eye, the IOL is known as phakic, otherwise it is a pseudophakic, or false lens.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulations.gov">Regulations.gov</a></td>
      <td>Regulations.gov is a U.S. Federal government web site that acts as an "Internet portal and document repository" that allows members of the public to participate in the rulemaking processes of some Federal government agencies.  \nThe site allows users to make public comments in response to notices of proposed rulemaking issued by participating agencies; such comments become part of the public record and may be displayed on the site.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Google_Contact_Lens">Google Contact Lens</a></td>
      <td>Google Contact Lens was a smart contact lens project announced by Google on 16 January 2014. The project aimed to assist people with diabetes by constantly measuring the glucose levels in their tears.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bionic_contact_lens">Bionic contact lens</a></td>
      <td>Bionic contact lenses are devices that, it is proposed by the manufacturers and developers, could provide a virtual display that could have a variety of uses from assisting the visually impaired to video gaming. The device will have the form of a conventional contact lens with added bionics technology in the form of augmented reality, with functional electronic circuits and infrared lights to create a virtual display allowing the viewer to see a computer-generated display superimposed on the world outside.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contact">Contact</a></td>
      <td>A contract is a legally enforceable agreement that creates, defines, and governs mutual rights and obligations among its parties. A contract typically involves the transfer of goods, services, money, or a promise to transfer any of those at a future date.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Keratitis">Keratitis</a></td>
      <td>Keratitis is a condition in which the eye's cornea, the clear dome on the front surface of the eye, becomes inflamed. The condition is often marked by moderate to intense pain and usually involves any of the following symptoms: pain, impaired eyesight, photophobia (light sensitivity), red eye and a 'gritty' sensation.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1 800 CONTACTS INC      Item 1A                Risk Factors       Please  consider  <font color="blue">carefully</font>  the  <font color="blue">following risk factors</font> and all other     information contained in this report</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue"><font color="blue">uncertainties</font> described</font>     below are risks that <font color="blue">the Company </font>currently believes to be material, but they     are not the only ones <font color="blue">the Company </font>faces</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font>     not <font color="blue">presently known</font> to <font color="blue">the Company </font>or that <font color="blue">the Company </font>currently believes     are <font color="blue">immaterial may also impair</font> its business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any of the following     <font color="blue">risks <font color="blue">could harm</font></font> the Company’s business, operating results and financial     condition</td>
    </tr>
    <tr>
      <td>This report contains forward-looking statements that involve     known and <font color="blue">unknown risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These statements relate to the     Company’s plans, <font color="blue">objectives</font>, <font color="blue">expectations</font> and <font color="blue">intentions</font></td>
    </tr>
    <tr>
      <td>The Company’s     actual  results  <font color="blue">could differ materially from</font> those discussed in these     statements</td>
    </tr>
    <tr>
      <td>Factors that <font color="blue">could contribute</font> to these <font color="blue">differences</font> include those     discussed below and elsewhere in this report</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       Risks Relating to Our Business       Continued  growth  of  “doctors only” lenses could compel <font color="blue">contact lens</font>     <font color="blue">manufacture</font>rs to adopt or expand a “doctors only” <font color="blue">distribution</font> strategy for     all or some of the lenses they <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>Until a few years ago, <font color="blue">substantially</font> all of the major <font color="blue">manufacture</font>rs of     <font color="blue"><font color="blue"><font color="blue">contact lens</font>es</font> refused</font> to <font color="blue">sell lenses</font> to <font color="blue">direct marketers</font>, including the     Company, and sought to prohibit their <font color="blue"><font color="blue">distributor</font>s</font> from doing so</td>
    </tr>
    <tr>
      <td>As a     result, <font color="blue">the Company </font><font color="blue">historically purchased</font> a substantial portion of its     products from unauthorized <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>Currently, <font color="blue">the Company </font>purchases     <font color="blue">products directly</font> from <font color="blue">manufacture</font>rs, including Johnson &amp; Johnson Vision     Care,  CIBA  Vision,  Bausch &amp;  Lomb and CooperVision, <font color="blue">as well as from</font>     <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>purchases the majority of its <font color="blue">products directly</font>     from  these <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>However, <font color="blue">the Company </font><font color="blue">occasionally purchases</font>     products  from  two  of  the  above <font color="blue">manufacture</font>rs through unauthorized     <font color="blue"><font color="blue">distributor</font>s</font> at a <font color="blue">lower cost</font> and <font color="blue">also purchases certain</font> other products     through unauthorized <font color="blue"><font color="blue">distributor</font>s</font> that are marketed as “doctors only” and     sold only to <font color="blue">eye care <font color="blue">practitioner</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>can purchase some, but not     all, “doctors only” lenses through unauthorized <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">current <font color="blue">supply <font color="blue">agreement</font>s</font> with</font> Johnson &amp; Johnson Vision Care     and <font color="blue">CIBA Vision </font>expire April 2007 and <font color="blue">September </font>2006, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Both     </font><font color="blue">manufacture</font>rs have stated a desire to extend the <font color="blue">supply <font color="blue">agreement</font>s</font>, and the     Company expects to renew these <font color="blue"><font color="blue">agreement</font>s prior</font> to the <font color="blue">expiration dates</font></td>
    </tr>
    <tr>
      <td>The     Company <font color="blue">also purchases directly from</font> Bausch &amp; Lomb as a result of a five     <font color="blue">year <font color="blue">settlement <font color="blue">agreement</font></font></font> that Bausch &amp; Lomb signed in 2001</td>
    </tr>
    <tr>
      <td>That settlement     <font color="blue"><font color="blue">agreement</font> will</font> expire in November 2006; however, <font color="blue">the Company </font>has received no     <font color="blue">indication</font>  that  Bausch &amp; Lomb will not sell to <font color="blue">the Company </font>after the     expiration of the <font color="blue">settlement <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes there is a risk     that <font color="blue">continued growth</font> of “doctors only” lenses could compel one or more of     these <font color="blue">manufacture</font>rs to switch back to a “doctors only” <font color="blue">distribution</font> strategy     for all or some of their lenses</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> of <font color="blue">the Company </font>to obtain     sufficient quantities of <font color="blue"><font color="blue">contact lens</font>es</font> at <font color="blue">competitive</font> prices would have a     material adverse effect on the Company’s business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">will continue</font> to experience order <font color="blue">cancellations due</font> to the     <font color="blue">prescription verification <font color="blue"><font color="blue">requirement</font>s</font></font> of the Fairness to Contact Lens     Consumers Act</td>
    </tr>
    <tr>
      <td>The federal Fairness to Contact Lens Consumer Act (“FCLCA”) established a     national  uniform  standard for both <font color="blue">eye care <font color="blue">practitioner</font>s</font> and direct     <font color="blue">marketers with</font> regard to releasing and <font color="blue">verifying consumer <font color="blue">contact lens</font></font>     <font color="blue"><font color="blue">prescriptions</font> as well as</font> other <font color="blue"><font color="blue">requirement</font>s</font> relating to the sale of contact     lenses</td>
    </tr>
    <tr>
      <td><font color="blue">The FCLCA </font>requires that <font color="blue"><font color="blue"><font color="blue">contact lens</font>es</font> only</font> be sold to consumers     <font color="blue">based on</font> a <font color="blue">valid prescription</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfying </font>this <font color="blue">prescription <font color="blue">requirement</font></font>     obligates the <font color="blue">seller either</font> to obtain a copy of the <font color="blue">prescription itself</font> or     to verify the <font color="blue">prescription by direct communication with</font> the customer’s     prescriber</td>
    </tr>
    <tr>
      <td>Although the FCLCA eliminated much of the <font color="blue">previous legal risk</font>     and <font color="blue">uncertainty associated with numerous differing</font> and <font color="blue">often ambiguous</font> or     archaic state laws and <font color="blue">regulations</font> that had <font color="blue"><font color="blue">previously</font> governed</font> the sale of     contact  lenses,  the  Company’s adherence to the FCLCA’s <font color="blue"><font color="blue">requirement</font>s</font>     nationwide results in it <font color="blue">canceling</font> a portion of its customers’ orders due to     their <font color="blue">prescriptions</font> being expired or <font color="blue">otherwise invalid</font></td>
    </tr>
    <tr>
      <td>Net sales for fiscal     2003, 2004 and 2005 were <font color="blue"><font color="blue"><font color="blue">negatively</font> impacted</font> by canceled orders due</font> to the     Company’s <font color="blue">prescription verification procedures</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">may continue</font> to <font color="blue">incur <font color="blue"><font color="blue">significant</font> legal</font></font> and <font color="blue"><font color="blue">professional</font> fees</font>     related to its <font color="blue">legal matters</font> and its efforts to <font color="blue"><font color="blue">proactively</font> influence</font> the     <font color="blue">industry on</font> its behalf and on behalf of its consumers</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>spent dlra6dtta4 million, dlra5dtta6 million and dlra4dtta7 million on legal and     <font color="blue">professional</font>  fees  in  fiscal 2003, 2004 and 2005, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>As a     percentage of net sales, legal and <font color="blue"><font color="blue">professional</font> fees</font> have decreased over the     last few years, <font color="blue">representing</font> 3dtta4prca, 2dtta6prca and 2dtta0prca of net sales in fiscal     2003, 2004 and 2005, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>During these years, <font color="blue">the Company </font>incurred     <font color="blue"><font color="blue">significant</font> legal</font> and <font color="blue"><font color="blue">professional</font> fees</font> related to <font color="blue">legal initiatives</font> and     <font color="blue">increased efforts</font>, including considerable <font color="blue">lobbying activities</font>, to overcome     the       20     ______________________________________________________________________       anti<font color="blue">competitive</font> barriers in the <font color="blue">industry on</font> the Company’s behalf and on     behalf of consumers</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>expects to continue to incur legal and     <font color="blue"><font color="blue">professional</font> fees</font> as it maintains efforts to <font color="blue">proactively</font> change the laws,     <font color="blue">regulations</font> and anti-<font color="blue">competitive</font> practices affecting the industry</td>
    </tr>
    <tr>
      <td>The     Company expects to increase its fiscal 2006 legal and <font color="blue"><font color="blue">professional</font> fees</font> from     the fiscal 2005 amount</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>obtains a large percentage of its <font color="blue">inventory from</font> a limited     number of suppliers</td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>seeks to reduce its <font color="blue">reliance on</font> any <font color="blue">one supplier by</font>     <font color="blue">establishing <font color="blue"><font color="blue">relationship</font>s with</font></font> a number of <font color="blue"><font color="blue">distributor</font>s</font>, <font color="blue">manufacture</font>rs and     other sources, <font color="blue">the Company </font>acquired from a <font color="blue">single <font color="blue">distributor</font> approximately</font>     22 percent, 44 percent and 42 percent of its <font color="blue"><font color="blue"><font color="blue">contact lens</font>es</font> purchased</font> in     fiscal 2003, 2004 and 2005, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">top three suppliers</font>     accounted for approximately 59 percent, 83 percent and 81 percent of the     Company’s <font color="blue">inventory purchased</font> in fiscal 2003, 2004 and 2005, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue"><font color="blue">continually</font> seeks</font> to <font color="blue">establish new <font color="blue"><font color="blue">relationship</font>s with</font> potential</font>     suppliers in order to obtain adequate inventory at <font color="blue">competitive</font> prices</td>
    </tr>
    <tr>
      <td>In     the event that these suppliers could no longer supply <font color="blue">the Company </font>with     <font color="blue"><font color="blue">contact lens</font>es</font>, there can be no assurance that <font color="blue">the Company </font><font color="blue">could secure</font>     other <font color="blue">adequate sources</font> of supply, or that <font color="blue">such supply could</font> be obtained on     <font color="blue">terms no less</font> favorable to <font color="blue">the Company </font>than its current supply, which could     <font color="blue">adversely</font>  affect <font color="blue">the Company </font><font color="blue">by increasing</font> its costs or, in the event     <font color="blue">adequate replacement supply cannot</font> be secured, reducing its net sales</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">may incur unforeseen costs</font> or not realize all of the anticipated     <font color="blue">benefits from</font> its <font color="blue"><font color="blue">relationship</font>s with</font> Johnson &amp; Johnson Vision Care and CIBA     Vision</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2002, <font color="blue">the Company </font>reached an <font color="blue"><font color="blue">agreement</font> with</font> Johnson &amp; Johnson     Vision Care to become an authorized retailer of Johnson &amp; Johnson Vision     Care <font color="blue"><font color="blue">contact lens</font>es</font> and <font color="blue">began buying direct from</font> Johnson &amp; Johnson Vision     Care during March 2003</td>
    </tr>
    <tr>
      <td>Prior to this, <font color="blue">the Company </font>became an authorized     retailer of <font color="blue">CIBA Vision </font><font color="blue"><font color="blue">contact lens</font>es</font> and <font color="blue">began buying direct from</font> CIBA     Vision</td>
    </tr>
    <tr>
      <td>These <font color="blue">direct <font color="blue">relationship</font>s</font> have lowered the Company’s product     <font color="blue">acquisition costs</font> and allowed it to <font color="blue">offer rebates</font> and other <font color="blue">incentives</font> not     <font color="blue"><font color="blue">previously</font> available</font> to its customers who wear lenses <font color="blue">manufacture</font>d by these     companies</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">also been able</font> to reduce its <font color="blue">inventory investment</font>     <font color="blue">by purchasing</font> a more <font color="blue">balanced mix</font> of <font color="blue">products at lower prices than</font> it has     <font color="blue">historically been able</font> to obtain <font color="blue">through indirect sources</font></td>
    </tr>
    <tr>
      <td>However, there is     no assurance that <font color="blue">the Company </font>will be able to continue to realize these     benefits or other anticipated benefits in the <font color="blue">future from</font> its <font color="blue">relationship</font>     with these <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">currently purchases</font> a portion of its products from unauthorized     <font color="blue"><font color="blue">distributor</font>s</font> and is not an <font color="blue">authorized <font color="blue">distributor</font></font> for some of the products     that it sells</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">Company  </font>believes that the price which it pays for <font color="blue">certain products</font> is     <font color="blue">sometimes higher than</font> those paid by <font color="blue">eye care <font color="blue">practitioner</font>s</font>, retail chains     and <font color="blue">mass <font color="blue">merchandisers</font></font>, who are able to <font color="blue">buy directly from</font> the <font color="blue">manufacture</font>rs     of  such  lenses  and who <font color="blue">benefit from</font> being allowed to <font color="blue">participate</font> in     cooperative <font color="blue">advertising</font> funds, coupon, sample, rebate and other marketing     and <font color="blue">promotional programs</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>has been able to obtain most     <font color="blue">contact lens</font> brands at <font color="blue">competitive</font> prices in <font color="blue">sufficient quantities on</font> a     regular basis, there can be no assurance that <font color="blue">the Company </font>will not encounter     <font color="blue"><font color="blue">difficult</font>ies</font> in the future</td>
    </tr>
    <tr>
      <td>The factors of price, availability and source of     the <font color="blue"><font color="blue">contact lens</font>es</font> are all <font color="blue"><font color="blue">consideration</font>s</font> in <font color="blue">deciding which lenses</font> to offer     for sale</td>
    </tr>
    <tr>
      <td>During the latter part of fiscal 2004, <font color="blue">the Company </font>decided to     <font color="blue">suspend sales</font> of a specific brand of lens, as <font color="blue">the Company </font>is unable to     obtain  sufficient  quantities of this <font color="blue">lens from anyone</font> other than the     <font color="blue">manufacture</font>r, who refuses to sell <font color="blue">the Company </font>this lens</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> of     <font color="blue">the Company </font>to obtain sufficient quantities of <font color="blue"><font color="blue">contact lens</font>es</font> at <font color="blue">competitive</font>     prices would have a material adverse effect on the Company’s business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Because <font color="blue">the Company </font>does not <font color="blue">manufacture</font> most of the <font color="blue"><font color="blue">contact lens</font>es</font> that it     sells, <font color="blue">the Company </font><font color="blue">cannot ensure</font> that all of the <font color="blue"><font color="blue">contact lens</font>es</font> it sells     meet all federal <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contact  </font>lenses are <font color="blue">regulated as <font color="blue">medical devices</font> by</font> the FDA Under the     Federal Food, Drug, and Cosmetic Act (the “FDC Act”), <font color="blue"><font color="blue">medical devices</font> must</font>     meet a number of <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, including the <font color="blue">requirement</font> that     they be cleared or <font color="blue">approved by</font> the FDA, be <font color="blue">manufacture</font>d in <font color="blue">accordance with</font>     good <font color="blue">manufacturing</font> practice <font color="blue">regulations</font>, be labeled in <font color="blue">compliance with</font>     <font color="blue">federal law</font>, and be <font color="blue">listed with</font> the FDA <font color="blue">The Company </font>attempts to ensure that     the lenses it buys <font color="blue">comply with</font> <font color="blue">federal law</font>s</td>
    </tr>
    <tr>
      <td>However, if it is not the     <font color="blue">manufacture</font>r, <font color="blue">the Company </font><font color="blue">cannot ensure</font> that the lenses it <font color="blue">sells complies</font>     with the FDC Act</td>
    </tr>
    <tr>
      <td>The <font color="blue">distribution</font> of <font color="blue">medical devices</font> that do not comply     with the FDC Act is unlawful and subjects the <font color="blue">distributor</font> and the devices     <font color="blue">themselves</font> to FDA <font color="blue"><font color="blue">regulatory</font> action</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">possible sanctions</font> include warning     <font color="blue">letters from</font> the FDA, injunction, civil penalties and <font color="blue">criminal <font color="blue">prosecution</font></font>,     as well as seizure and/or destruction of the <font color="blue"><font color="blue">contact lens</font>es</font></td>
    </tr>
    <tr>
      <td>It is possible that the FDA could consider certain of the <font color="blue"><font color="blue">contact lens</font>es</font> the     Company sells to be misbranded or <font color="blue">adulterated</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contact  </font>lenses are <font color="blue">regulated by</font> the FDA as “<font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>” <font color="blue">The FDA     </font>classifies <font color="blue">medical devices</font> as Class I, Class II or <font color="blue">Class III </font>and regulates     them to varying degrees, with Class I <font color="blue">medical devices</font> subject to the least     amount of regulation and <font color="blue">Class III </font><font color="blue">medical devices</font> subject to the most     stringent  <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> generally apply only to the     <font color="blue">manufacturing</font> of <font color="blue"><font color="blue">contact lens</font>es</font> and, therefore, do not <font color="blue">directly impact</font> the     <font color="blue">direct marketing</font> <font color="blue">operations</font> of the Company</td>
    </tr>
    <tr>
      <td>Federal <font color="blue">regulations</font> also require     the labels on “<font color="blue">medical devices</font>” to <font color="blue">contain adequate <font color="blue">instructions</font></font> for their     safe and proper use</td>
    </tr>
    <tr>
      <td>However, there is an <font color="blue">exemption from</font> this <font color="blue">requirement</font>     for  medical  devices  the  use  of which is not <font color="blue">safe except under</font> the     <font color="blue">supervision</font> of a <font color="blue"><font color="blue">practitioner</font> licensed by law</font> to direct the use of such     device</td>
    </tr>
    <tr>
      <td>Devices which fall within this <font color="blue">exception must contain as</font> part of     their labeling the statement “Caution: Federal law restricts this device to     sale by or on the order of (physician or other <font color="blue">licensed <font color="blue">practitioner</font></font>),” the     blank  to  be  filled in with the word physician or other <font color="blue">practitioner</font>     <font color="blue">authorized by</font> the law of the state in which the <font color="blue">practitioner</font> practices to     use or order the use of the device</td>
    </tr>
    <tr>
      <td>The FDA considers <font color="blue"><font color="blue">contact lens</font>es</font> to     qualify for this labeling exemption; however, a device bearing this legend     that is <font color="blue">dispensed without</font> a <font color="blue">prescription may</font> be considered <font color="blue">misbranded by</font> the     <font color="blue">FDA Potential </font>penalties for <font color="blue">misbranding</font> include warning <font color="blue">letters from</font> the     FDA, seizure, injunction, civil penalties or <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>To date, the FDA     has not taken any <font color="blue">such action against</font> the Company</td>
    </tr>
    <tr>
      <td>A portion of the Company’s sales may be found not to <font color="blue">comply with</font> state laws     and <font color="blue">regulations</font> concerning the delivery and sale of <font color="blue"><font color="blue">contact lens</font>es</font></td>
    </tr>
    <tr>
      <td>Although the FCLCA overrides state laws or <font color="blue">regulations</font> that purport to     impose stricter <font color="blue">prescription verification procedures</font> on <font color="blue">direct marketers</font> or     that <font color="blue">otherwise conflict with</font> the <font color="blue">general purposes</font> and <font color="blue">objectives</font> of the     FCLCA, the sale and delivery of <font color="blue"><font color="blue">contact lens</font>es</font> to consumers may also be     subject to limited <font color="blue">regulation by</font> the state where the customer is located</td>
    </tr>
    <tr>
      <td>For example, a substantial number of states require that <font color="blue"><font color="blue"><font color="blue">contact lens</font>es</font> only</font>     be sold by persons licensed or registered to do so under that state’s laws</td>
    </tr>
    <tr>
      <td>Also, the FCLCA, allows states to set the prescription length—as long as it     is <font color="blue">longer than one year</font></td>
    </tr>
    <tr>
      <td>Such state laws or <font color="blue">regulations</font> may or may not run     afoul of the FCLCA or other federal or constitutional <font color="blue"><font color="blue">requirement</font>s</font> depending     on their <font color="blue">particular provisions</font></td>
    </tr>
    <tr>
      <td>Neither <font color="blue">the Company </font>nor any of its employees     is a licensed eye care <font color="blue">professional</font> in many of the states in which the     Company does business</td>
    </tr>
    <tr>
      <td>Any <font color="blue">action <font color="blue">brought against</font></font> <font color="blue">the Company </font><font color="blue">based on</font> its failure to <font color="blue">comply with</font>     applicable state laws and <font color="blue">regulations</font> could result in <font color="blue"><font color="blue">significant</font> fines</font> to     the Company, <font color="blue">the Company </font>being <font color="blue">prohibited from</font> making sales in a particular     state  or <font color="blue">the Company </font>being required to <font color="blue">comply with</font> such laws or could     <font color="blue">constitute</font>  a  <font color="blue">misdemeanor</font></td>
    </tr>
    <tr>
      <td>Such  required <font color="blue">compliance could</font> result in     (i) <font color="blue"><font color="blue">increased cost</font>s</font> to the Company, (ii) the <font color="blue">inability</font> to sell to customers     at all in a particular state if <font color="blue">the Company </font>cannot <font color="blue">comply with</font> such state’s     laws       22     ______________________________________________________________________       and (iii) <font color="blue">misdemeanor</font> penalties and <font color="blue">civil fines</font></td>
    </tr>
    <tr>
      <td>The occurrence of any of     the above results could have a material adverse effect on the Company’s     ability to sell <font color="blue"><font color="blue">contact lens</font>es</font> and to continue to operate profitably</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">manufacturing</font> facilities and products are subject to stringent     regulation  by the FDA, and <font color="blue">the Company </font>may not be able to develop and     <font color="blue">manufacture</font> viable, high quality <font color="blue"><font color="blue">contact lens</font>es</font> for sale to consumers that     meets all federal <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Pursuant to the FDC Act, and <font color="blue">implementing</font> <font color="blue">regulations</font>, the FDA regulates the     testing, <font color="blue">manufacturing</font>, labeling, <font color="blue">distribution</font>, importation and promotion of     <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Non<font color="blue">compliance with</font> applicable <font color="blue"><font color="blue">requirement</font>s</font> can result in,     among other things, fines, injunctions, civil penalties, recall or seizure     of  products,  total  or <font color="blue">partial suspension</font> of product <font color="blue">distribution</font> or     importation, failure of the <font color="blue">government</font> to <font color="blue">grant premarket clearance</font> or     approval for devices, withdrawal of <font color="blue">marketing <font color="blue">clearances</font></font> or approvals and     <font color="blue">criminal <font color="blue">prosecution</font></font></td>
    </tr>
    <tr>
      <td>The FDA also has the authority to request the recall,     repair, replacement or refund of the cost of any device <font color="blue">manufacture</font>d or     <font color="blue">distributed by</font> the Company</td>
    </tr>
    <tr>
      <td>Under the FDC Act, clearance or <font color="blue">approval by</font> the FDA is required prior to the     <font color="blue">commercialization</font> of a medical device</td>
    </tr>
    <tr>
      <td>Before a new device can be introduced     into the US market, it must receive from the FDA premarket notification     <font color="blue">clearance under</font> Section 510(k) of the FDC Act or premarket approval pursuant     to the more costly and time-consuming premarket approval application (PMA)     procedure</td>
    </tr>
    <tr>
      <td>For any devices that are cleared through the 510(k) process,     <font color="blue"><font color="blue">modification</font>s</font> or <font color="blue">enhancements</font> that could <font color="blue"><font color="blue">significant</font>ly</font> affect safety or     <font color="blue"><font color="blue">effective</font>ness</font>, or <font color="blue">constitute</font> a major change in the <font color="blue">intended use</font> of the     device,  will require new 510(k) submissions</td>
    </tr>
    <tr>
      <td>While <font color="blue">less expensive</font> and     time-consuming than obtaining PMA clearance, securing 510(k) clearance may     involve the submission of a <font color="blue">substantive review</font> of six months or more</td>
    </tr>
    <tr>
      <td>Any     products  <font color="blue">manufacture</font>d or <font color="blue">distributed pursuant</font> to 510(k) clearance are     subject to pervasive and <font color="blue">continuing <font color="blue">regulation by</font></font> the FDA, including record     keeping <font color="blue"><font color="blue">requirement</font>s</font> and reporting of adverse experience with the use of the     device</td>
    </tr>
    <tr>
      <td>Most of ClearLab’s products have 510(k) clearance, and any <font color="blue">new products</font>     <font color="blue">under <font color="blue">development</font></font> to be marketed in the <font color="blue">United States </font>will undergo clinical     studies to support a 510(k) or PMA There is <font color="blue">no certainty</font> that clinical     studies involving <font color="blue">new products</font> will be completed in a <font color="blue">timely manner</font> or that     the data and information obtained will be sufficient to support the filing     of a PMA or 510(k) clearance</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot assure</font> that it will be able     to obtain <font color="blue">necessary <font color="blue">clearances</font></font> and approvals to <font color="blue">market new devices</font> or any     other products <font color="blue">under <font color="blue">development</font></font> on a <font color="blue">timely basis</font>, if at all, and delays in     receipt or failure to receive such <font color="blue">clearances</font> or approvals, the loss of     <font color="blue">previously</font> received <font color="blue">clearances</font>, or failure to <font color="blue">comply with</font> existing or future     <font color="blue">regulatory</font>  <font color="blue"><font color="blue">requirement</font>s</font>  could  have a material adverse effect on the     Company’s business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As  a <font color="blue">manufacture</font>r of <font color="blue">medical devices</font> <font color="blue">for the US </font>market, <font color="blue">ClearLab </font>is     required to <font color="blue">register with</font> the FDA and <font color="blue">comply with</font> the FDA’s Code of Federal     Regulations quality system <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> require that     <font color="blue">ClearLab </font>maintain <font color="blue">manufacturing</font>, testing and <font color="blue">control activities records</font> in a     <font color="blue">prescribed manner</font> and maintain <font color="blue">careful records</font> of, and <font color="blue">control over</font>, device     <font color="blue">design <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">ClearLab </font>and <font color="blue">the Company </font>are required to comply     with FDA <font color="blue"><font color="blue">requirement</font>s</font> for labeling and <font color="blue">promoting products</font></td>
    </tr>
    <tr>
      <td><font color="blue">ClearLab </font>is     subject to <font color="blue">periodic inspections by</font> the FDA and can be subjected to a number     of <font color="blue"><font color="blue">regulatory</font> action</font>s if the FDA finds <font color="blue">ClearLab </font>to be not in <font color="blue">compliance with</font>     <font color="blue">applicable laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>believes that <font color="blue">ClearLab </font>may not     be operating in <font color="blue">compliance with</font> <font color="blue">applicable laws</font> and <font color="blue">regulations</font>, it can     record its <font color="blue">observations on</font> a <font color="blue">Form FDA </font>483; place <font color="blue">ClearLab </font><font color="blue">under observation</font>     and re-inspect the facilities; institute proceedings to issue a warning     <font color="blue">letter apprising</font> of volatile conduct; detain or seize products; mandate a     recall; enjoin future violations; and <font color="blue">assess civil</font> and <font color="blue">criminal penalties</font>     against ClearLab, its officers or its employees</td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">appropriate</font>     <font color="blue">circumstances</font>, the FDA could withdraw <font color="blue">clearances</font> or approvals</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       The Company, through a wholly owned subsidiary, conducts activities as an     initial  importer  of  <font color="blue"><font color="blue"><font color="blue">contact lens</font> products</font> which also</font> are subject to     <font color="blue">regulation by</font> the FDA The quality system <font color="blue">regulations</font> require that the     subsidiary   develop   <font color="blue">appropriate</font>  practices  to  address  <font color="blue">management</font>     responsibilities, control of <font color="blue">documents</font> and handling, storage and records     maintenance,  among  other  things</td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font>to ClearLab, the FDA may     <font color="blue">periodically</font> inspect the subsidiary</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that the subsidiary is     not in <font color="blue">compliance with</font> the <font color="blue">applicable laws</font> and <font color="blue">regulations</font>, the FDA may     institute enforcement actions, such as issuance of a <font color="blue">Form FDA </font>483 or warning     letter or impose the more <font color="blue">severe penalties as described</font> above</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>and importers of <font color="blue">medical devices</font> for marketing in the United     States must also <font color="blue">comply with</font> medical device reporting <font color="blue"><font color="blue">requirement</font>s</font> that     companies report to the FDA any incident in which its product may have     caused or contributed to a death or <font color="blue">serious injury</font>, or in which its product     <font color="blue">malfunction</font>ed and, if the <font color="blue">malfunction</font> were to recur, it would be likely to     cause or contribute to a death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td>Any adverse <font color="blue">regulatory</font>     action or the failure of <font color="blue">ClearLab </font>or the above mentioned subsidiary to     <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> could have a material <font color="blue">adverse affect on</font>     the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot assure</font> that it will not incur <font color="blue">significant</font> costs to comply     with laws and <font color="blue">regulations</font> in the future or that laws and <font color="blue">regulations</font> will     not have a material adverse effect upon the Company’s business, financial     condition or results of operation</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">manufacturing</font> facilities and products are subject to stringent     regulation  <font color="blue">by various foreign jurisdictions</font> in which its products are     <font color="blue">manufacture</font>d and/or sold</td>
    </tr>
    <tr>
      <td>ClearLab’s products also are subject to regulation in other countries in     which its products are sold</td>
    </tr>
    <tr>
      <td>The laws and <font color="blue">regulations</font> of <font color="blue">such countries</font>     <font color="blue">range from comprehensive medical</font> device <font color="blue">approval procedures such as</font> those     described above to <font color="blue">simple requests</font> for <font color="blue">product data</font> or <font color="blue">certifications</font></td>
    </tr>
    <tr>
      <td>The     number  and  scope  of  these  laws and <font color="blue">regulations</font> are increasing</td>
    </tr>
    <tr>
      <td>Under the system established by the     Directive, all <font color="blue">medical devices</font> other <font color="blue">than active implants</font> and in vitro     <font color="blue">diagnostic products currently must qualify</font> for CE marking</td>
    </tr>
    <tr>
      <td>“CE marking”     means  the <font color="blue">manufacture</font>r certifies that its product bearing the CE mark     satisfies all <font color="blue"><font color="blue">requirement</font>s</font> essential for the product to be considered safe     and fit for its <font color="blue">intended purpose</font></td>
    </tr>
    <tr>
      <td>Although member <font color="blue">countries must accept</font> for marketing <font color="blue">medical devices</font> bearing     a CE marking without imposing further <font color="blue"><font color="blue">requirement</font>s</font> related to <font color="blue">product safety</font>     and performance, each country may require the use of its own language or     labels and <font color="blue">instructions</font> for use</td>
    </tr>
    <tr>
      <td>Member countries can <font color="blue">impose additional</font>     <font color="blue"><font color="blue">requirement</font>s</font> as long as they do not violate the <font color="blue">Directive </font>or <font color="blue">constitute</font>     technical barriers to trade</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>approvals from foreign <font color="blue">regulatory</font>     <font color="blue">authorities may</font> be required for <font color="blue">international</font> sale of the Company’s products     in  non-EU  countries</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  <font color="blue">comply with</font> applicable <font color="blue">regulatory</font>     <font color="blue"><font color="blue">requirement</font>s</font> can result in the loss of <font color="blue">previously</font> received approvals and     other sanctions and could have a material adverse effect on the Company’s     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Consumer <font color="blue">acceptance</font> of the Company’s <font color="blue">manufacture</font>d products may not meet the     Company’s <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>The Company’s wholly owned subsidiary, ClearLab, is the Company’s principal     marketing <font color="blue">organization</font> for its wholesale <font color="blue">manufacturing</font> and <font color="blue">distribution</font>     business, <font color="blue">focusing on</font> the marketing of its own <font color="blue"><font color="blue">contact lens</font> products</font> to     major  retailers  and <font color="blue"><font color="blue">distributor</font>s</font>, as well as providing some contract     <font color="blue">manufacturing</font> <font color="blue">capacity</font> for other <font color="blue">contact lens</font> <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>ClearLab’s     <font color="blue">development</font> and <font color="blue">manufacturing</font> <font color="blue">capabilities</font> also provide <font color="blue">the Company </font>access     to current and future <font color="blue"><font color="blue">contact lens</font> products</font>, which <font color="blue">the Company </font><font color="blue">may introduce</font>     to the US <font color="blue">market should</font> the Company’s access to <font color="blue"><font color="blue">contact lens</font>es</font> from the     major  <font color="blue">contact lens</font> <font color="blue">manufacture</font>rs be disrupted, curtailed or otherwise     <font color="blue"><font color="blue">negatively</font> impacted</font>, or if the <font color="blue">manufacture</font>rs do not provide <font color="blue">the Company </font>with     contact  lenses  at <font color="blue">competitive</font> pricing and with <font color="blue">competitive</font> marketing     support</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>intends to continue to increase its <font color="blue">product offerings</font>     to the <font color="blue">international</font>       24     ______________________________________________________________________       markets</td>
    </tr>
    <tr>
      <td>However, consumer <font color="blue">acceptance</font> of the Company’s <font color="blue">manufacture</font>d products     may not meet the Company’s <font color="blue">expectations</font>, and it <font color="blue">cannot assure</font> that the     Company will be able to increase its <font color="blue">product offerings</font> in the <font color="blue">international</font>     markets</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may not be able to establish a <font color="blue">sufficient network</font> of eye care     <font color="blue">practitioner</font>s to <font color="blue">provide <font color="blue">contact lens</font> eye exams</font> to its customers who have     expired <font color="blue">contact lens</font> <font color="blue">prescriptions</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>is <font color="blue">continually</font> taking steps to <font color="blue">minimize canceled orders</font>,     including continued <font color="blue">development</font> of a <font color="blue">doctor referral network</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is     <font color="blue">currently expanding</font> its national <font color="blue">doctor referral network</font> with select optical     retail  chains  and  in<font color="blue">dependent</font> <font color="blue">practitioner</font>s and plans to have 1cmam000     <font color="blue">locations by</font> the end of 2006</td>
    </tr>
    <tr>
      <td>Under this <font color="blue">referral program</font>, when a current or     <font color="blue">potential customer</font> needs a <font color="blue">new <font color="blue">contact lens</font> prescription</font>, <font color="blue">the Company </font>can     <font color="blue">facilitate</font> the process of obtaining an <font color="blue">eye <font color="blue">examination</font> through</font> this network     of  providers</td>
    </tr>
    <tr>
      <td>This  process  minimizes  the <font color="blue">interruptions</font> in product     <font color="blue">consumption</font> for the consumer and improves the Company’s ability to capture     new  customers and retain its <font color="blue">current customers</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">the Company </font>is not     successful in expanding its national <font color="blue">doctor referral network</font>, net sales     could be <font color="blue"><font color="blue">negatively</font> impacted</font> by the Company’s <font color="blue">inability</font> to <font color="blue">recapture orders</font>     <font color="blue">canceled due</font> to expired <font color="blue">contact lens</font> <font color="blue">prescriptions</font></td>
    </tr>
    <tr>
      <td>The Company’s quarterly results are likely to <font color="blue">vary based upon</font> the level of     sales and <font color="blue">marketing activity</font> in any <font color="blue">particular quarter</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>currently  expenses all <font color="blue"><font color="blue">advertising</font> costs</font>, including all     direct-mail <font color="blue"><font color="blue">advertising</font> costs</font>, when the <font color="blue"><font color="blue">advertising</font> first</font> takes place</td>
    </tr>
    <tr>
      <td>As a     result,  quarter-to-quarter  <font color="blue">comparisons</font> are affected by the timing of     <font color="blue">television</font>, radio and Internet <font color="blue">advertisements</font> and by the mailing of its     printed <font color="blue">advertisements</font> within and <font color="blue">between quarters</font></td>
    </tr>
    <tr>
      <td>The volume of mailings     and other <font color="blue"><font color="blue">advertising</font> may vary</font> in <font color="blue">different quarters</font> and from year to year     <font color="blue">depending on</font> the Company’s <font color="blue">assessment</font> of <font color="blue">prevailing market opportunities</font></td>
    </tr>
    <tr>
      <td>The  Company’s operating results for any <font color="blue">particular quarter</font> may not be     <font color="blue">indicative</font> of future operating results</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">the Company </font>typically     <font color="blue">decreases</font>  <font color="blue">advertising</font>  <font color="blue">expenditures</font>  in the <font color="blue">fourth quarter due</font> to the     <font color="blue">increased cost</font> to <font color="blue">advertise during</font> this period</td>
    </tr>
    <tr>
      <td>As a result, the Company, in     the past has, and in the future expects to, <font color="blue">generate lower revenues</font> in the     <font color="blue">fourth quarter than</font> in the <font color="blue">preceding third quarter</font></td>
    </tr>
    <tr>
      <td>You should not rely on     quarter-to-quarter <font color="blue">comparisons</font> of the Company’s results of <font color="blue">operations</font> as an     <font color="blue">indication</font> of its <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In the future the Company’s results of     <font color="blue">operations</font> may be below the <font color="blue">expectations</font> of <font color="blue">public market analysts</font></td>
    </tr>
    <tr>
      <td>This in     the  past  has  and in the <font color="blue">future could</font> cause the <font color="blue">trading price</font> of the     Company’s <font color="blue">common stock</font> to fall <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">retail sale</font> of <font color="blue"><font color="blue">contact lens</font>es</font> is highly <font color="blue">competitive</font> and certain of the     Company’s <font color="blue">competitors</font> are large, <font color="blue">national <font color="blue">optical chains</font></font> that have greater     <font color="blue">resources than</font> the Company</td>
    </tr>
    <tr>
      <td>The <font color="blue">retail sale</font> of <font color="blue"><font color="blue">contact lens</font>es</font> is a highly <font color="blue">competitive</font> and fragmented     industry</td>
    </tr>
    <tr>
      <td>Traditionally, <font color="blue"><font color="blue">contact lens</font>es</font> were sold to <font color="blue">customers almost</font>     exclusively by <font color="blue">eye care <font color="blue">practitioner</font>s</font> in <font color="blue"><font color="blue">connection with</font> providing them</font> an     eye  <font color="blue">examination</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for patients and the revenue related to     providing <font color="blue"><font color="blue">contact lens</font>es</font> to those customers <font color="blue"><font color="blue">significant</font>ly</font> increased as     <font color="blue">optical chains</font> and large <font color="blue">discount retailers began providing optical services</font>     and has <font color="blue">further intensified with</font> the entry of <font color="blue">direct marketers</font> such as the     Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that the <font color="blue">eye care profession suffers from</font> a     surplus  of  <font color="blue">eye care <font color="blue">practitioner</font>s</font> and that the resulting <font color="blue">competitive</font>     pressure has <font color="blue">been exacerbated by</font> the <font color="blue">increased prevalence</font> of <font color="blue">retail optical</font>     chains,  mass  <font color="blue">merchandisers</font>  and  <font color="blue">direct marketers</font></td>
    </tr>
    <tr>
      <td>Consequently, the     <font color="blue">competition</font> amongst <font color="blue">eye care <font color="blue">practitioner</font>s</font> to acquire customers and the     <font color="blue">competition</font> to <font color="blue">provide replacement lenses</font> to <font color="blue">such customers</font> has intensified</td>
    </tr>
    <tr>
      <td>To  a  lesser  extent, <font color="blue">the Company </font>also <font color="blue">competes with</font> <font color="blue">manufacture</font>rs of     <font color="blue">eyeglasses</font> and providers of other <font color="blue">vision correction</font>, including refractive     <font color="blue">surgical procedures</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       The  Company’s  principal  <font color="blue">competitors</font>  include  <font color="blue">ophthalmologists</font>  and     <font color="blue">optometrists</font> in <font color="blue">private practice</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">also <font color="blue">competes with</font> national</font>     <font color="blue">optical chains</font>, such as Pearle Vision, LensCrafters and National Vision     Association,  and <font color="blue">mass <font color="blue">merchandisers</font></font>, such as Wal-Mart, Sam’s Club and     Costco</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font><font color="blue">competes with</font> other <font color="blue">direct marketers</font> of     <font color="blue"><font color="blue">contact lens</font>es</font>, including on-line <font color="blue">direct marketers</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may face     increased  <font color="blue">competition</font>  in  the <font color="blue">future from</font> new entrants in the direct     marketing business, which may include <font color="blue">national <font color="blue">optical chains</font></font> and mass     <font color="blue">merchandisers</font>, some of which may have <font color="blue"><font color="blue">significant</font>ly</font> greater <font color="blue">resources than</font>     the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that many of its <font color="blue">competitors</font>, including <font color="blue">most eye care</font>     <font color="blue">practitioner</font>s, <font color="blue">national <font color="blue">optical chains</font></font> and <font color="blue">mass <font color="blue">merchandisers</font></font>, have direct     supply arrangements with all of the <font color="blue">contact lens</font> <font color="blue">manufacture</font>rs which in some     <font color="blue">cases afford</font> those <font color="blue">competitors</font> with better pricing terms, access to supply     and other sales and <font color="blue">marketing programs</font></td>
    </tr>
    <tr>
      <td>In addition, some of the <font color="blue">competitors</font>     are <font color="blue"><font color="blue">significant</font>ly</font> larger in <font color="blue">overall revenues</font> and have <font color="blue"><font color="blue">significant</font>ly</font> greater     <font color="blue">resources than</font> the Company</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> of <font color="blue">the Company </font>to <font color="blue">effective</font>ly     compete within the industry would have a material adverse effect on the     Company’s business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The demand for <font color="blue"><font color="blue">contact lens</font>es</font> could be <font color="blue">substantially</font> reduced if <font color="blue">alternative</font>     <font color="blue">technologies</font> to <font color="blue">permanently</font> correct <font color="blue">vision gain</font> in <font color="blue">popularity</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also encounters <font color="blue">competition</font> from <font color="blue">manufacture</font>rs of <font color="blue">eyeglasses</font> and     from <font color="blue">alternative</font> <font color="blue">technologies</font>, such as surgical refractive procedures,     including <font color="blue">new refractive laser procedures such as</font> PRK, or photo refractive     <font color="blue">keratectomy</font>,  and  LASIK, or laser in situ <font color="blue">keratomileusis</font></td>
    </tr>
    <tr>
      <td>If surgical     refractive procedures become increasingly accepted as an <font color="blue">effective</font> and safe     technique for permanent <font color="blue">vision correction</font>, they could <font color="blue">substantially</font> reduce     the demand for <font color="blue"><font color="blue">contact lens</font>es</font> by enabling patients to avoid the <font color="blue">ongoing cost</font>     and <font color="blue">inconvenience</font> of <font color="blue"><font color="blue">contact lens</font>es</font></td>
    </tr>
    <tr>
      <td>Accordingly, these procedures or other     <font color="blue">alternative</font> <font color="blue">technologies</font> may be developed in the future, which may cause a     substantial decline in the number of <font color="blue"><font color="blue">contact lens</font> wearers</font> and thus harm the     Company’s business</td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in the cost of shipping, postage or credit <font color="blue">card processing could</font>     harm the Company’s business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>ships its products to <font color="blue">customers by</font> <font color="blue">United States </font>mail and other     <font color="blue">overnight delivery</font> and <font color="blue">surface services</font></td>
    </tr>
    <tr>
      <td>It <font color="blue">generally invoices</font> the costs of     delivery and <font color="blue">parcel shipments directly</font> to <font color="blue">customers as separate shipping</font> and     <font color="blue">handling charges</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font><font color="blue">uses direct mailings</font> to advertise     its products and receives a majority of <font color="blue">payments from customers using</font> credit     cards</td>
    </tr>
    <tr>
      <td>Any increases in shipping, postal or credit <font color="blue">card processing rates</font>     could  harm  the  Company’s operating results as it may not be able to     <font color="blue">effective</font>ly pass such increases on to its customers</td>
    </tr>
    <tr>
      <td>Similarly, strikes or     other service <font color="blue">interruptions</font> by these <font color="blue">shippers could limit</font> the Company’s     ability to market or deliver its <font color="blue">products on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>The Company’s business could be harmed if it is required to collect state     sales tax on the sale of all products</td>
    </tr>
    <tr>
      <td>At  present, <font color="blue">the Company </font><font color="blue">only collects sales</font> or other similar taxes in     <font color="blue">connection with</font> the sale of its products to <font color="blue">consumers located</font> inside the     state of Utah</td>
    </tr>
    <tr>
      <td>A <font color="blue">successful assertion by one</font> or more states that the     Company should have collected or should be <font color="blue">collecting sales taxes on</font> the     sale of its <font color="blue">products could</font> result in <font color="blue">additional costs</font> and <font color="blue">administrative</font>     expenses to <font color="blue">the Company </font>and <font color="blue">corresponding</font> price increases to its customers,     which <font color="blue">could harm</font> the Company’s business</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       <font color="blue">The Company </font>faces an inherent risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims     in the event that the use of the products it <font color="blue">manufacture</font>rs or sell results     in <font color="blue">personal injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>faces an inherent risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims     in the event that the use of the products it <font color="blue">manufacture</font>s and/or sells     results in <font color="blue">personal injury</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>has not experienced any     <font color="blue"><font color="blue">significant</font> losses due</font> to <font color="blue">product <font color="blue">liability</font></font> claims, it <font color="blue">cannot assure</font> that it     will  not  experience <font color="blue">such losses</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains     insurance against <font color="blue">product <font color="blue">liability</font></font> claims, but it cannot be certain that     <font color="blue">such coverage will</font> be adequate to cover any <font color="blue">liabilities</font> that it may incur,     or that such insurance <font color="blue">will continue</font> to be <font color="blue">available on terms</font> acceptable to     the Company</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">brought against</font> <font color="blue">the Company </font>in excess of     available insurance coverage, or any claim that results in <font color="blue">significant</font>     adverse publicity, <font color="blue">could harm</font> the Company’s business</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>conducts its retail <font color="blue">operations</font> through a single <font color="blue">distribution</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of the Company’s US <font color="blue">retail inventory</font> is stored and     <font color="blue">shipped from</font> its <font color="blue">distribution</font> center in <font color="blue">Salt Lake City</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>depends     in large part on the <font color="blue">orderly operation</font> of this receiving and <font color="blue">distribution</font>     process, which depends, in turn, on adherence to <font color="blue">shipping schedules</font> and     <font color="blue">effective</font> <font color="blue">management</font> of the <font color="blue">distribution</font> center</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may not be able     to <font color="blue">accurately</font> anticipate all of the changing demands that its expanding     <font color="blue">operations</font>  will  impose  on its receiving and <font color="blue">distribution</font> system</td>
    </tr>
    <tr>
      <td>In     addition,  <font color="blue">events beyond</font> the Company’s control, such as <font color="blue">disruption</font>s in     <font color="blue">operations</font> due to labor dis<font color="blue">agreement</font>s, shipping problems, fires or natural     disasters, may harm the Company’s business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>is  subject to <font color="blue">certain risks associated with</font> its foreign     <font color="blue">operations</font> that <font color="blue">could harm</font> its revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">ClearLab </font>International and <font color="blue">ClearLab </font>UK <font color="blue">acquisitions</font>, the     Company has <font color="blue">significant</font> <font color="blue">operations</font> in <font color="blue">Singapore </font>and in the <font color="blue">United Kingdom</font></td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>risks are inherent in <font color="blue">international</font> <font color="blue">operations</font>, including the     following:  the  <font color="blue">Company  </font>may have <font color="blue">difficult</font>y enforcing <font color="blue">agreement</font>s and     collecting  receivables through certain foreign legal systems; foreign     customers  may have <font color="blue">longer payment cycles than customers</font> in the United     States; tax rates in <font color="blue">certain foreign countries may exceed</font> those in the     United  States,  and  foreign  earnings  may be subject to withholding     <font color="blue"><font color="blue">requirement</font>s</font>  or the imposition of tariffs, exchange controls or other     restrictions; general economic and <font color="blue">political conditions</font> in countries where     <font color="blue">the Company </font>operates may have an adverse effect on its <font color="blue">operations</font> in those     countries; <font color="blue">the Company </font>may find it <font color="blue">difficult</font> to manage a large <font color="blue">organization</font>     <font color="blue">spread throughout various countries</font>; <font color="blue">the Company </font>may find it <font color="blue">difficult</font> to     interpret  foreign  and  domestic  tax laws and anticipate <font color="blue">foreign tax</font>     <font color="blue">liabilities</font>; and <font color="blue">the Company </font>may find it <font color="blue">difficult</font> to <font color="blue">comply with</font> other     <font color="blue">foreign laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">the Company </font>continues to expand its business globally, success will     depend, in part, on its ability to anticipate and <font color="blue">effective</font>ly manage these     and other risks</td>
    </tr>
    <tr>
      <td>The occurrence of any of the <font color="blue">foregoing risks could</font> have a     <font color="blue">significant</font> effect on the Company’s <font color="blue">international</font> <font color="blue">operations</font> and, as a     result, its revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Currency <font color="blue">exchange rate fluctuations could</font> have an adverse effect on the     Company’s financial results</td>
    </tr>
    <tr>
      <td>The  Company <font color="blue">faces foreign <font color="blue">currency risk</font>s primarily as</font> a result of its     acquired  <font color="blue">Singapore </font>and <font color="blue">United Kingdom</font> <font color="blue">operations</font> and the <font color="blue">intercompany</font>     <font color="blue">balances between</font> its US and these <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations     </font>in exchange rates between the US dollar and the <font color="blue">Singapore </font>dollar and the     US dollar and the British <font color="blue">pound could lead</font> to <font color="blue">additional currency exchange</font>     losses or gains on the <font color="blue">intercompany</font> balances and <font color="blue"><font color="blue">transaction</font>s denominated</font> in     currencies other than the <font color="blue">functional currency</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has not entered     into any foreign currency derivative financial instruments; however, it may     choose to do so in the future in an effort to manage or hedge its foreign     <font color="blue">currency risk</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       <font color="blue">The Company </font>may be required to reduce the carrying value of its intangible     assets  if  events and <font color="blue">circumstances</font> indicate the <font color="blue">remaining balance</font> of     <font color="blue"><font color="blue">intangible assets</font> may</font> not be recoverable</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has a <font color="blue">significant</font> amount of goodwill and other <font color="blue">intangible assets</font>     <font color="blue">recorded on</font> its <font color="blue">balance sheet as</font> a result of its <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>SFAS Nodtta 142,     “Goodwill and Other Intangible Assets,” provides that goodwill and other     <font color="blue">intangible assets</font> with indefinite lives be tested for <font color="blue">impairment annually</font>     <font color="blue">using market values</font>, or more <font color="blue">frequently</font> if <font color="blue">impairment indicators</font> arise</td>
    </tr>
    <tr>
      <td>In     assessing the <font color="blue">recoverability</font> of goodwill and other <font color="blue">intangible assets</font>, the     Company must make <font color="blue">assumptions</font> regarding estimated <font color="blue">future cash flows</font> and     other factors to determine the <font color="blue">fair market value</font> of the <font color="blue">respective assets</font></td>
    </tr>
    <tr>
      <td>If these estimates or their related <font color="blue">assumptions</font> change in the future, the     Company may be required to <font color="blue">record impairment charges</font> for these assets</td>
    </tr>
    <tr>
      <td>If     required,  these <font color="blue">charges would</font> be included in operating income</td>
    </tr>
    <tr>
      <td>If the     Company determines that <font color="blue">significant</font> impairment has occurred, it would be     required to write off the impaired portion of <font color="blue">intangible assets</font>, which could     have a material adverse effect on its operating results in the period in     which the write-off occurs</td>
    </tr>
    <tr>
      <td>The  Company’s intellectual <font color="blue">property rights</font> may be challenged, and the     Company does not have any <font color="blue">property rights</font> in the 1-800 CONTACTS telephone     number or <font color="blue">the Internet </font><font color="blue">addresses</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>conducts its <font color="blue">direct marketing</font> business under the <font color="blue">various trade</font>     names and service marks, including “1-800 CONTACTS” <font color="blue">The Company </font>has taken     steps to register and protect these marks and believes that such marks have     <font color="blue">significant</font>  value and are an important factor in the marketing of its     products</td>
    </tr>
    <tr>
      <td>To this end, <font color="blue">the Company </font>has <font color="blue">secured trademark registration</font> for     the “1-800 CONTACTS” name</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has obtained the rights to various     <font color="blue">tele<font color="blue">phone numbers</font></font>, including but not limited to the 1-800 CONTACTS telephone     number</td>
    </tr>
    <tr>
      <td>However, <font color="blue">under applicable</font> FCC rules and <font color="blue">regulations</font>, <font color="blue">the Company </font>    does  not have and cannot acquire any <font color="blue">property rights</font> to the telephone     numbers</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>does not expect to lose the right to use the telephone     numbers; however, there can be no assurance in this regard</td>
    </tr>
    <tr>
      <td>The loss of the     right to use the 1-800 CONTACTS number or other <font color="blue">specific <font color="blue">tele<font color="blue">phone numbers</font></font></font>     would have a material adverse effect on the Company’s business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font>has obtained     the rights to <font color="blue">international</font> equivalents for the 1-800 CONTACTS phone number;     however, like the 1-800 CONTACTS number, <font color="blue">the Company </font>does not have and     cannot acquire any <font color="blue">property rights</font> in these <font color="blue">tele<font color="blue">phone numbers</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also has obtained the rights to various Internet <font color="blue">addresses</font>,     including  but  not limited to www</td>
    </tr>
    <tr>
      <td><font color="blue">contacts</font></td>
    </tr>
    <tr>
      <td><font color="blue">contactlenses</font></td>
    </tr>
    <tr>
      <td>As with     <font color="blue">phone numbers</font>, <font color="blue">the Company </font>does not have and cannot acquire any property     rights  in Internet <font color="blue">addresses</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>does not expect to lose the     ability to use <font color="blue">the Internet </font><font color="blue">addresses</font>; however, there can be no assurance in     this  regard and <font color="blue">such loss would</font> have a material adverse effect on the     Company’s business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may not be able to complete its <font color="blue">milestones</font> and <font color="blue">obligations</font> in a     <font color="blue">timely manner</font> under the Japanese <font color="blue">license <font color="blue">agreement</font></font> and may not receive the     amount of <font color="blue">license fees</font> and royalties that it presently anticipates under the     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2004, <font color="blue">the Company </font>signed an <font color="blue">agreement</font> which grants Menicon,     Japan’s largest in<font color="blue">dependent</font> <font color="blue">contact lens</font> <font color="blue">manufacture</font>r, exclusive rights to     develop,  <font color="blue">manufacture</font> and market certain disposable <font color="blue"><font color="blue">contact lens</font>es</font> and     related <font color="blue">intellectual property</font> in Japan</td>
    </tr>
    <tr>
      <td>Under the terms of the <font color="blue">agreement</font>,     Menicon <font color="blue">licenses from</font> <font color="blue">the Company </font><font color="blue">different types</font> of <font color="blue">intellectual property</font>,     including  <font color="blue">contact lens</font> material, <font color="blue">manufacturing</font> <font color="blue">technology</font> and related     knowledge</td>
    </tr>
    <tr>
      <td>In <font color="blue">consideration</font>, Menicon is expected to <font color="blue">pay nonrefundable</font>     <font color="blue">license fees</font> of dlra18 million, of which dlra5 million was paid in <font color="blue">December </font>2004,     dlra3 million in <font color="blue">December </font>2005 and dlra2 million in January 2006</td>
    </tr>
    <tr>
      <td>The remaining     dlra8 million is expected to be paid over the next two to <font color="blue">four years as</font> the     Company continues to fulfill its <font color="blue">obligations</font> and as <font color="blue">corresponding</font> <font color="blue">milestones</font>     relating to Japanese <font color="blue">regulatory</font> approval and Menicon’s launch of the product     in the Japanese market are       28     ______________________________________________________________________       met</td>
    </tr>
    <tr>
      <td>Of the     dlra10 million that has been received, dlra3 million is <font color="blue">based on</font> <font color="blue">achievement</font> of a     <font color="blue">specific milestone</font> and the balance received <font color="blue">represents</font> a portion of the     <font color="blue">guaranteed license fee</font></td>
    </tr>
    <tr>
      <td>Upon <font color="blue">completion</font> of this <font color="blue">agreement</font>, <font color="blue">the Company </font>will     recognize the <font color="blue">remaining milestone payments as</font> the agreed upon <font color="blue">milestones</font> are     achieved</td>
    </tr>
    <tr>
      <td><font color="blue">If Menicon </font>has not received <font color="blue">regulatory</font> approval on or before <font color="blue">December </font>31,     2009, it may return all <font color="blue">intellectual property</font> covered by the <font color="blue">agreement</font> and     in-process <font color="blue">regulatory</font> approvals to the Company, and <font color="blue">the Company </font>may pursue     the Japanese <font color="blue">market on</font> its own and terminate the exclusive <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>the terms of the <font color="blue">agreement</font>, Menicon <font color="blue">will also pay royalties</font> for a period of     at least 15 years from the <font color="blue">product launch</font> date in Japan on <font color="blue"><font color="blue">contact lens</font>es</font>     sold that were <font color="blue">manufacture</font>d using the licensed <font color="blue">technology</font>, with a guaranteed     minimum of dlra5 million per year beginning the earlier of the <font color="blue">second year</font>     after <font color="blue">product launch</font> or 2012</td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> does not include the sale of any     of the Company’s current equipment, facilities or <font color="blue">capacity</font> and is limited to     the Japanese <font color="blue">contact lens</font> market</td>
    </tr>
    <tr>
      <td>In the event that <font color="blue">the Company </font>is not able to complete its <font color="blue">milestones</font> and     <font color="blue">obligations</font> in a <font color="blue">timely manner</font>, or in the event Menicon is not able to     achieve <font color="blue">regulatory</font> approval, <font color="blue">the Company </font>may not receive a portion of the     amount of <font color="blue">license fees</font> and royalties that it presently anticipates under the     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Risks Relating to the <font color="blue"><font color="blue">Internet  </font>   </font>  The  <font color="blue">Company  </font>is  <font color="blue">dependent</font>  on its telephone, Internet and <font color="blue">management</font>     information systems for the sale and <font color="blue">distribution</font> of <font color="blue"><font color="blue">contact lens</font>es</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">success depends</font>, in part, on its ability to <font color="blue">provide prompt</font>,     accurate and complete service to its <font color="blue">customers on</font> a <font color="blue">competitive</font> basis and     its  ability  to purchase and promote products, manage inventory, ship     products, manage sales and <font color="blue">marketing activities</font> and maintain <font color="blue">efficient</font>     <font color="blue">operations</font> through its telephone and <font color="blue">proprietary</font> <font color="blue">management</font> information     systems</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>conducts all of its telephone and Internet <font color="blue">operations</font>     from a <font color="blue">single location</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> <font color="blue">disruption</font> in its telephone, <font color="blue"><font color="blue">Internet  </font>   </font>or <font color="blue">management</font> information systems <font color="blue">could harm</font> the Company’s <font color="blue">relations with</font>     its customers and the ability to manage its <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>From time to time,     <font color="blue">the Company </font>has experienced temporary <font color="blue">interruptions</font> in its <font color="blue">telephone service</font>     as a result of the <font color="blue">technical problems</font> experienced by its long-distance     carrier</td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font><font color="blue">interruptions</font>  may  occur  in  the  future and such     <font color="blue">interruptions</font> may harm the Company’s business</td>
    </tr>
    <tr>
      <td>Furthermore, extended or     repeated <font color="blue">reliance on</font> the Company’s back-up computer systems may harm its     business</td>
    </tr>
    <tr>
      <td>There can be no assurance that the Company’s back-up system will     be sufficient to prevent an interruption in the Company’s <font color="blue">operations</font> in the     event of <font color="blue">disruption</font> in the Company’s <font color="blue">management</font> information systems, and an     extended <font color="blue">disruption</font> in the <font color="blue">management</font> information systems could <font color="blue">adversely</font>     affect  the  Company’s  business,  financial  condition and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  Company’s  success is <font color="blue">dependent</font>, in part, <font color="blue">on continued use</font> of the     Internet</td>
    </tr>
    <tr>
      <td><font color="blue">The Internet </font>is <font color="blue">rapidly evolving</font></td>
    </tr>
    <tr>
      <td>A decrease in the growth of Internet usage     would harm the Company’s business</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors may inhibit growth</font>     in Internet usage, limit visits to the Company’s Internet <font color="blue">addresses</font> or limit     <font color="blue">orders placed through</font> its website: inadequate Internet <font color="blue">infrastructure</font>;     security  and  privacy  concerns; inconsistent quality of service; and     <font color="blue">unavailability</font> of low cost, high speed service</td>
    </tr>
    <tr>
      <td>The  Company’s  success is <font color="blue">dependent</font>, in part, upon the ability of the     <font color="blue">Internet  </font><font color="blue">infrastructure</font> to <font color="blue">support increased use</font></td>
    </tr>
    <tr>
      <td>The performance and     <font color="blue">re<font color="blue">liability</font></font> of <font color="blue">the Internet </font><font color="blue">may decline as</font> the number of <font color="blue">users increase</font>s or     the bandwidth <font color="blue"><font color="blue">requirement</font>s</font> of <font color="blue">users increase</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Internet </font>has experienced a     variety of <font color="blue">outages due</font> to damage to portions of its <font color="blue">infrastructure</font></td>
    </tr>
    <tr>
      <td>If     outages or delays occur <font color="blue">frequently</font> in the future, Internet usage, including     usage of the Company’s website, could grow slowly or decline</td>
    </tr>
    <tr>
      <td>Even if the       29     ______________________________________________________________________       necessary <font color="blue">infrastructure</font> or <font color="blue">technologies</font> are developed, <font color="blue">the Company </font>may have     to spend considerable amounts to adapt its <font color="blue">solutions accordingly</font></td>
    </tr>
    <tr>
      <td>Online <font color="blue">security breaches</font> <font color="blue">could harm</font> the Company’s business</td>
    </tr>
    <tr>
      <td>The <font color="blue">secure transmission</font> of <font color="blue">confidential</font> information over <font color="blue">the Internet </font>is     essential  to  maintain  <font color="blue">consumer confidence</font> in the Company’s website</td>
    </tr>
    <tr>
      <td><font color="blue">Substantial  </font>or  ongoing  security  breaches  of  its  system or other     Internet-based  systems  could  <font color="blue"><font color="blue">significant</font>ly</font>  harm  its business</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">penetration</font> of the Company’s <font color="blue">network security</font> or other <font color="blue">misappropriation</font> of     its users’ personal information could subject <font color="blue">the Company </font>to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>The     Company may be liable for claims <font color="blue">based on</font> unauthorized purchases with credit     card information, <font color="blue">impersonation</font> or other similar fraud claims</td>
    </tr>
    <tr>
      <td>Claims could     also  be  based  on other misuses of personal information, such as for     <font color="blue">unauthorized marketing purposes</font></td>
    </tr>
    <tr>
      <td>These claims could result in <font color="blue">litigation</font> and     financial <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Security <font color="blue">breaches also could damage</font> the Company’s     reputation  and expose it to a risk of loss or <font color="blue">litigation</font> and possible     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">relies on licensed encryption</font> and <font color="blue">authentication</font>     <font color="blue">technology</font>  to effect <font color="blue">secure transmission</font> of <font color="blue">confidential</font> information,     including credit <font color="blue">card numbers</font></td>
    </tr>
    <tr>
      <td>It is possible that advances in computer     <font color="blue">capabilities</font>,  <font color="blue">new discoveries</font> or other <font color="blue">development</font>s could result in a     compromise  or breach of the <font color="blue">technology</font> used by <font color="blue">the Company </font>to protect     customer <font color="blue">transaction</font> data</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may incur substantial expense to <font color="blue">protect against</font> and remedy     <font color="blue">security breaches</font> and their <font color="blue">consequences</font></td>
    </tr>
    <tr>
      <td>A party that is able to <font color="blue">circumvent</font>     our  security  systems  could  steal  <font color="blue">proprietary</font> information or cause     <font color="blue">interruptions</font>  in  the  Company’s  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s insurance     policies’ limits may not be adequate to reimburse it for losses caused by     <font color="blue">security breaches</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot guarantee</font> that its <font color="blue">security measures</font>     will prevent <font color="blue">security breaches</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>regulation and legal <font color="blue">uncertainties</font> relating to <font color="blue">the Internet </font>and     online commerce could <font color="blue">negatively</font> impact the Company’s business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Currently, there are few laws or <font color="blue">regulations</font> directly applicable to the     Internet or online commerce on the Internet, and the <font color="blue">laws governing</font> the     Internet that exist <font color="blue">remain largely unsettled</font></td>
    </tr>
    <tr>
      <td>Recently, the US Congress     enacted Internet laws regarding online children’s privacy, copyrights and     taxation</td>
    </tr>
    <tr>
      <td>This  or similar <font color="blue">legislation</font> could dampen growth in use and     <font color="blue">acceptance</font>  of  the  Internet</td>
    </tr>
    <tr>
      <td>Due to the increasing <font color="blue">popularity</font> of the     Internet, it is possible that <font color="blue">additional laws</font> and <font color="blue">regulations</font> may be enacted     <font color="blue">with respect</font> to the Internet, covering issues such as user privacy, pricing,     taxation,  content, copyrights, <font color="blue">distribution</font>, antitrust and quality of     products and services</td>
    </tr>
    <tr>
      <td>The adoption or <font color="blue">modification</font> of laws or <font color="blue">regulations</font>     applicable to <font color="blue">the Internet </font><font color="blue">could harm</font> the Company’s business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, several telecommunications carriers have requested that the     <font color="blue">Federal Communications Commission </font><font color="blue">regulate telecommunications over</font> the     Internet</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">increasing use</font> of <font color="blue">the Internet </font>and the burden it has     <font color="blue">placed on</font> the current telecommunications <font color="blue">infrastructure</font>, telephone carriers     have requested the FCC to regulate Internet <font color="blue">service providers</font> and impose     <font color="blue">access fees on</font> those providers</td>
    </tr>
    <tr>
      <td><font color="blue">If the FCC </font><font color="blue">imposes access fees</font>, the costs of     using <font color="blue">the Internet </font><font color="blue">could increase dramatically</font></td>
    </tr>
    <tr>
      <td>This could result in the     <font color="blue">reduced use</font> of <font color="blue">the Internet </font>as a medium for commerce, which <font color="blue">could harm</font> the     Company’s business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font><font color="blue">technology</font> could <font color="blue">adversely</font> affect the operation of the Company’s     website</td>
    </tr>
    <tr>
      <td>The  Internet,  online  commerce  and  online  <font color="blue">advertising</font> markets are     <font color="blue">characterized by rapidly</font> changing <font color="blue">technologies</font>, evolving industry standards,     frequent  new  product and <font color="blue">service introductions</font> and changing customer     <font color="blue">preferences</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">future success will depend on</font> its ability to     adapt to rapidly changing       30     ______________________________________________________________________       <font color="blue">technologies</font> and address its customers’ changing <font color="blue">preferences</font></td>
    </tr>
    <tr>
      <td>However, the     Company may experience <font color="blue"><font color="blue">difficult</font>ies</font> that delay or prevent it being able to     do so</td>
    </tr>
  </tbody>
</table>